The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis

• Status: Completed
• Trial end date: 2017-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to access the effect (week 12/week 24) of puerarin injection on carotid intima-media thickness (CIMT) in rheumatoid arthritis (RA) patients despite routine anti-rheumatic treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chengdu PLA General Hospital
• Treatments: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Aspirin; Prednisone; Protective Agents; Puerarin

Criteria

Inclusion Criteria:

• patients with a definite diagnose of rheumatoid arthritis(RA) were included if they met the classification criteria for RA established by the American Rheumatism Association (ACR) and European League Against Rheumatism (EULAR) in 2010

• aged from 18 to 75 years

• without conflict to the written, informed consent signed prior to the enrollment

• no severe hepatic or renal disorders

• no known carotid artery stenosis

• no coagulation disorders

• no hypertension

Exclusion Criteria:

• being in pregnancy, lactation period or under a pregnancy plan

• being allergic to the test drug

• not compatible for the trial medication

• without full legal capacity